Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial
Authors
Keywords
-
Journal
Lancet Respiratory Medicine
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2021-02-07
DOI
10.1016/s2213-2600(20)30566-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Type I and Type III Interferons – Induction, Signaling, Evasion, and Application to Combat COVID-19
- (2020) Annsea Park et al. Cell Host & Microbe
- Predicting infectious SARS-CoV-2 from diagnostic samples
- (2020) Jared Bullard et al. CLINICAL INFECTIOUS DISEASES
- Comparative replication and immune activation profiles of SARS-CoV-2 and SARS-CoV in human lungs: an ex vivo study with implications for the pathogenesis of COVID-19
- (2020) Hin Chu et al. CLINICAL INFECTIOUS DISEASES
- Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial
- (2020) Philippe Gautret et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- COVID-19 and emerging viral infections: The case for interferon lambda
- (2020) Ludmila Prokunina-Olsson et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial
- (2020) Ivan Fan-Ngai Hung et al. LANCET
- Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study
- (2020) Fei Zhou et al. LANCET
- Remdesivir for the Treatment of Covid-19 — Preliminary Report
- (2020) John H. Beigel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards
- (2020) Bernard La Scola et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- Low performance of rapid antigen detection test as frontline testing for COVID-19 diagnosis
- (2020) Anaïs Scohy et al. JOURNAL OF CLINICAL VIROLOGY
- Type I and Type III IFN Restrict SARS-CoV-2 Infection of Human Airway Epithelial Cultures
- (2020) Abigail Vanderheiden et al. JOURNAL OF VIROLOGY
- Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients
- (2020) Jérôme Hadjadj et al. SCIENCE
- SARS-CoV-2 viral load predicts COVID-19 mortality
- (2020) Elisabet Pujadas et al. Lancet Respiratory Medicine
- A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures
- (2020) Kenneth H. Dinnon et al. NATURE
- Inborn errors of type I IFN immunity in patients with life-threatening COVID-19
- (2020) Qian Zhang et al. SCIENCE
- Autoantibodies against type I IFNs in patients with life-threatening COVID-19
- (2020) Paul Bastard et al. SCIENCE
- REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19
- (2020) David M. Weinreich et al. NEW ENGLAND JOURNAL OF MEDICINE
- Admission D-dimer levels, D-dimer trends, and outcomes in COVID-19
- (2020) Leonard Naymagon et al. THROMBOSIS RESEARCH
- Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial
- (2020) Phillip D Monk et al. Lancet Respiratory Medicine
- Interferon Lambda: Modulating Immunity in Infectious Diseases
- (2017) Mohammedyaseen Syedbasha et al. Frontiers in Immunology
- IFNλ is a potent anti‐influenza therapeutic without the inflammatory side effects of IFNα treatment
- (2016) Sophia Davidson et al. EMBO Molecular Medicine
- Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: A randomized phase 2b study (LIRA-B)
- (2016) Henry L.Y. Chan et al. JOURNAL OF HEPATOLOGY
- A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection
- (2014) Andrew J. Muir et al. JOURNAL OF HEPATOLOGY
- A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus
- (2013) Ludmila Prokunina-Olsson et al. NATURE GENETICS
- Effect of oseltamivir, zanamivir or oseltamivir–zanamivir combination treatments on transmission of influenza in households
- (2012) Fabrice Carrat et al. ANTIVIRAL THERAPY
- Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
- (2009) Dongliang Ge et al. NATURE
- Genetic variation in IL28B and spontaneous clearance of hepatitis C virus
- (2009) David L. Thomas et al. NATURE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search